Under the terms of their strategic partnership agreement, Valneva will pay LimmaTech an upfront payment of €10 million in exchange for an exclusive worldwide license for the development, manufacturing and commercialization of Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis.
